Company intelligence / Profile preview
Guangzhou Patronus Biotech
Guangzhou, Guangdong, Chinapmc.ncbi.nlm.nih.gov ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Patronus has multiple first-in-class or best-in-class prophylactic vaccine candidates in early-stage human studies for major infectious diseases including COVID–19, shingles, and RSV. The company’s U-VLP™ platform is designed to overcome traditional limitations of VLPs by enabling broader pathogen coverage and higher yields. No late-stage or commercialized products as of May 2025.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Virus-Like Particle (VLP) vaccinesGenetically engineered subunit vaccinesMultivalent vaccines
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Guangzhou Patronus Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Guangzhou Patronus Biotech.